Evidence map›Paper›PMID 40664780›Full record

ArticleScientific reports2025

Exploring the mechanism of metabolic cell death-related genes AKR1C2 and MAP1LC3A as biomarkers in Parkinson's disease.

Jia Fu, Jing Zhao, Xue Zhao, Na Mi, Chao Zhang, Xueying Li, Lei Wu, Lige Han, Yali Zhang, Lifen Yao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jia Fu *The First Affiliated Hospital of Harbin Medical University, Harbin, 150080, Heilongjiang, China.
Jing Zhao *The First Affiliated Hospital of Harbin Medical University, Harbin, 150080, Heilongjiang, China.
Xue ZhaoThe First Affiliated Hospital of Harbin Medical University, Harbin, 150080, Heilongjiang, China.
Na MiChifeng Municipal Hospital, Chifeng, 024000, Inner Mongolia Autonomous Region, China.
Chao ZhangThe First Affiliated Hospital of Harbin Medical University, Harbin, 150080, Heilongjiang, China.
Xueying LiThe First Affiliated Hospital of Harbin Medical University, Harbin, 150080, Heilongjiang, China.
Lei WuThe First Affiliated Hospital of Harbin Medical University, Harbin, 150080, Heilongjiang, China.
Lige HanThe First Affiliated Hospital of Harbin Medical University, Harbin, 150080, Heilongjiang, China.
Yali ZhangChifeng Municipal Hospital, Chifeng, 024000, Inner Mongolia Autonomous Region, China. a8350028@126.com.
Lifen YaoThe First Affiliated Hospital of Harbin Medical University, Harbin, 150080, Heilongjiang, China. 600749@hrbmu.edu.cn.ORCID http://orcid.org/0000-0002-8809-6523

Funding

Heilongjiang Provincial Natural Science Foundation NO. ZD2023H004National Natural Science Foundation of China NO.82471259Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals of Inner Mongolia Academy of Medical Sciences 2023090101, 2024GLLH0988
6 · The paper itself

Abstract

There is a strong relationship between metabolic cell death (MCD) and neurodegenerative diseases. However, the involvement of metabolic cell death (MCD)-related genes (MCDRGs) in Parkinson's disease (PD) pathogenesis remains poorly analyzed. Integrating PD-associated differentially expressed genes (DEGs) from GSE7621 with MCDRGs, we identified key biomarkers through protein-protein interaction networks and machine learning. Diagnostic performance was validated through nomogram analysis. Subsequent analyses included functional enrichment, immune profiling, drug prediction, and single-cell RNA sequencing. AKR1C2 and MAP1LC3A were identified as potential biomarkers. A nomogram with superior diagnostic performance was constructed. Gene set enrichment analysis indicated that both biomarkers were linked to the "Parkinson's disease". Further, immune infiltration revealed that AKR1C2 had the remarkably strongest positive correlation with M2 macrophages. Moreover, benzo[a]pyrene-1,6-dione, mestranol, and paraoxon-methyl might be potential therapeutic agents for PD. Single-cell RNA-seq analysis demonstrated endothelial-specific expression, with MAP1LC3A and AKR1C2 exhibiting distinct temporal regulation during differentiation. AKR1C2 and MAP1LC3A were identified as potential biomarkers associated with MCD in PD. These results offer fresh concepts for PD prevention and diagnosis.

Indexed as

Microtubule-Associated ProteinsParkinson DiseaseBiomarkersCell DeathGene Expression ProfilingGene Expression RegulationGene Regulatory NetworksHumansProtein Interaction MapsBiomarkersMicrotubule-Associated ProteinsDiagnostic performanceMachine learningMetabolic cell deathParkinson’s diseaseSingle-cell RNA sequencing

Identifiers

PMID40664780
PMCPMC12263998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.